It has been confirmed that the CHEK2 gene plays a crucial role in the DNA damage response (DDR) pathway encoding the regulatory kinase CHK2 in the HRR of double-strand breaks (14), and mutations in DDR genes can result in differential responses of prostate cancer to PARP inhibitors (15). The gene discussed is CHEK2; the disease is prostate carcinoma.